SFRP5 and endometrioid adenocarcinoma: In our series, hypermethylation of the Wnt antagonists (DKK1, DKK2, SFRP1, SFRP4, SFRP5, and WIF1) were observed with a significant prevalence in mucinous and endometrioid carcinomas.